The West Midlands Bladder Cancer Prognosis Programme: rationale and design

Area of Science:

• Uro-oncology
• Cancer epidemiology
• Clinical trial methodology

Background:

• Understanding bladder cancer determinants is crucial for reducing recurrence, progression, and mortality.
• Lifestyle factors' role in post-diagnosis bladder cancer recurrence and progression requires further investigation.
• Current histopathological prognostication is limited; molecular markers need refinement for clinical utility.

Purpose of the Study:

• To describe the rationale and design of the Bladder Cancer Prognosis Programme (BCPP).
• To demonstrate the capability of the BCPP design in a real-world setting.
• To investigate lifestyle factors, molecular markers, and supplement efficacy in bladder cancer.

Main Methods:

• Prospective longitudinal cohort study of newly diagnosed bladder cancer patients in the West Midlands, UK.
• Collection of lifestyle data, histopathological information, molecular markers, and health-related quality of life.
• Establishment of a comprehensive bladder cancer bio-repository and a randomized clinical trial on selenium and vitamin E.

Main Results:

• Recruited 771 patients (68% of eligible) since December 2005, with 331 currently followed via questionnaires.
• Obtained blood, urine, and tumor tissue specimens from 92%, 80%, and 80% of patients, respectively.
• Demonstrated successful integration of the study into routine clinical work, achieving high recruitment and data/specimen collection rates.

Conclusions:

• The BCPP design facilitates integration into routine clinical workflows, enabling high patient recruitment and robust data/specimen collection.
• The study's methodology provides a potential model for investigating other urological and oncological malignancies.
• This comprehensive approach aids in understanding bladder cancer prognosis and may inform future therapeutic strategies.